Response to: Correspondence on ‘Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch)’
Response to: Correspondence on ‘Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch)’. // Annals of the Rheumatic Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S0003496726038227?dgcid=rss_sd_all
Response to: Correspondence on ‘Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch)’. Annals of the Rheumatic Diseases. https://www.sciencedirect.com/science/article/pii/S0003496726038227?dgcid=rss_sd_all
“Response to: Correspondence on ‘Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch)’.” Annals of the Rheumatic Diseases.
@article{article97413,
title = {Response to: Correspondence on ‘Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch)’},
journal = {Annals of the Rheumatic Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S0003496726038227?dgcid=rss_sd_all}
}